Merck in early discussions to sell new COVID-19 pill to Canada

The U.S. pharmaceutical giant Merck & Co. says it is in early discussions with the federal government to sell it stocks of the company's experimental COVID-19 drug.

The company says its new pill can cut the risk of hospitalization or death by 50%

This undated image provided by Merck & Co. shows their new antiviral medication, which is being reviewed by Health Canada. (Merck & Co./The Associated Press)

The U.S. pharmaceutical giant Merck & Co. says it is in early discussions with the federal government to sell it stocks of the company's new COVID-19 drug.

Merck announced on Oct. 1 that it had developed a pill that can cut the risk of hospitalization or death by half in people with mild to moderate cases of COVID-19.

The company says its new pill, called molnupiravir, can disrupt the genetic material of the virus before it begins duplicating. It is not believed to be effective in severe cases.

"We are in active discussions with the government of Canada to basically look at securing an agreement to secure supply for molnupiravir for Canada," said Jennifer Chan, Merck Canada's vice-president of policy and government affairs.

WATCH | Merck Canada vice-president Jennifer Chan speaks to CBC's Power & Politics about the company's new COVID-19 drug

Merck Canada says it's in discussions with the federal government to come to deal to secure supply of its COVID-19 pill

10 months ago
Duration 8:19
Merck Canada vice-president Jennifer Chan joins Power & Politics to discuss molnupiravir, which if approved could be the first pill to treat COVID-19.

While the company says the pill can be an effective tool to help COVID-19 patients, no data about the drug have been released publicly or peer-reviewed by other scientists.

The company has submitted its preliminary data to Health Canada, among other national health agencies, but it has not been approved for use.

The U.S., which is also in the process of reviewing the drug, has reached a deal to buy 1.7 million courses of molnupiravir at a cost of approximately $866 each.

Chan said Merck will sell the drug internationally based on a "global tiered pricing strategy," which will adjust prices for the drug based on a nation's ability to pay.


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?